ONL Therapeutics

ONL Therapeutics (ONL) is a clinical stage biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal diseases and conditions. By advancing a novel breakthrough technology designed to protect photoreceptors against apoptotic and inflammatory cell death, ONL is pioneering an entirely new approach to preserving sight. It is the first and only company focused on preventing the death of retinal cells - the root cause of vision loss and the leading cause of blindness. Based on its industry-leading expertise in photoreceptor protection, ONL is developing breakthrough treatments for serious, vision-threatening retinal diseases and conditions. Lead therapeutic candidate, ONL1204, is a first-in-class small molecule peptide initially being for the protection of photoreceptors in retinal detachment. Preclinical data to date for ONL1204 demonstrates the drug's ability to protect photoreceptors against the apoptosis process triggered by retinal detachment.